ATIM-04. A MULTI-INSTITUTIONAL PILOT STUDY OF PROPHYLACTIC CRANIAL TUMOR-TREATING FIELDS FOR PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER

摘要

BACKGROUNDBrain metastases are common in patients diagnosed with small cell lung cancer (SCLC). Prophylactic cranial irradiation (PCI) has been shown to potentially improve survival in patients with extensive-stage small cell lung cancer (ES-SCLC) but has detrimental effects on quality-of-life (QoL). Tumor treating fields (TTFields) are a regional non-invasive, antimitotic treatment with minimal toxicity, approved for recurrent and newly diagnosed glioblastoma. Prophylactic cranial TTFields may allow for sufficient intracranial control and prevent the formation of brain metastases with minimal late cognitive effects potentially improving survival and QoL for patients with ES-SCLC.